文献速递心境障碍

睾酮治疗与男性抑郁症状缓解的相关性:系统综述与荟萃分析

Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis.
PubMed 文献 · JAMA Psychiatry · 2019-01-01

该系统综述与荟萃分析纳入27项随机安慰剂对照试验共1890名男性,发现睾酮治疗较安慰剂显著减轻抑郁症状(Hedges g=0.21,95%CI 0.10-0.32),疗效比值比OR=2.30(95%CI 1.30-4.06),可接受性与安慰剂无显著差异(OR=0.79,95%CI 0.61-1.01)。

要点

  • 睾酮治疗与男性抑郁症状显著减轻相关,效应量小但具统计学意义。
  • 睾酮治疗的有效率显著优于安慰剂(OR=2.30,95%CI 1.30-4.06)。
  • 高剂量方案(>0.5 g/wk)且基线症状变异低时效果更稳定。

核心结论

  • 睾酮治疗对男性抑郁症状具有减轻效果和疗效,尤其在较高剂量方案和精心选择的样本中。

研究设计与样本

  • 系统综述与荟萃分析,纳入27项随机安慰剂对照临床试验,共1890名男性,覆盖广泛年龄范围及性腺功能减退或正常男性。

主要发现

  • 与安慰剂相比,睾酮治疗显著减轻抑郁症状(Hedges g=0.21;95%CI 0.10-0.32)。
  • 睾酮治疗的有效率显著优于安慰剂(OR=2.30;95%CI 1.30-4.06)。
  • 睾酮治疗与安慰剂的可接受性无显著差异(OR=0.79;95%CI 0.61-1.01)。
  • 荟萃回归模型提示睾酮治疗与剂量及基线症状变异性存在显著交互作用。
  • 在最保守偏倚情景下,当剂量大于0.5 g/wk且症状变异性保持低水平时,睾酮治疗仍显著。

关键数值与推荐

  • 主要结局为睾酮治疗有效性(治疗后标准化评分差)、疗效(评分降低50%或以上的应答患者比例)和可接受性(因任何原因退出的患者比例)。

临床怎么用

  • 对于男性抑郁症状,睾酮治疗可作为一种替代或辅助选择,尤其在高剂量方案和筛选合适的患者中。
  • 需注意纳入RCT的异质性,更多以抑郁为主要终点的预注册试验尚待开展。

局限性

  • 纳入的随机对照试验存在异质性。
  • 需要更多明确以抑郁为主要终点并考虑相关调节因素的预注册试验。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

IMPORTANCE: Countering depressive disorders is a public health priority. Currently, antidepressants are the first-line treatment, although they show modest effects. In men, testosterone treatment is a controversial alternative or adjunct treatment option. OBJECTIVES: To examine the association of testosterone treatment with alleviation of depressive symptoms in men and to clarify moderating effects of testosterone status, depression status, age, treatment duration, and dosage. DATA SOURCES: English-language studies published in peer-reviewed journals identified from PubMed/Medline, Embase, Scopus, PsychINFO, and the Cochrane Controlled Trials Register from database inception to March 5, 2018, using the search terms testosterone, mood, administration, dosage, adverse effects, deficiency, standards, therapeutic use, therapy, treatment, and supplementation. STUDY SELECTION: Randomized placebo-controlled clinical trials (RCTs) of testosterone treatment that together cover a broad age range and hypogonadal or eugonadal men reporting depressive symptoms on psychometrically validated depression scales. DATA EXTRACTION AND SYNTHESIS: Of 7690 identified records, 469 were evaluated against full study inclusion criteria after removing duplicates, reviews, and studies that did not examine male patients or testosterone. Quality assessment and data extraction from the remaining 27 RCTs were performed. MAIN OUTCOMES AND MEASURES: Primary outcomes were testosterone treatment effectiveness (standardized score difference after treatment), efficacy (proportion of patients who responded to testosterone treatment with a score reduction of 50% or greater), and acceptability (proportion of patients who withdrew for any reason). RESULTS: Random-effects meta-analysis of 27 RCTs including 1890 men suggested that testosterone treatment is associated with a significant reduction in depressive symptoms compared with placebo (Hedges g, 0.21; 95% CI, 0.10-0.32), showing an efficacy of odds ratio (OR), 2.30 (95% CI, 1.30-4.06). There was no significant difference between acceptability of testosterone treatment and placebo (OR, 0.79; 95% CI, 0.61-1.01). Meta-regression models suggested significant interactions for testosterone treatment with dosage and symptom variability at baseline. In the most conservative bias scenario, testosterone treatment remained significant whenever dosages greater than 0.5 g/wk were administered and symptom variability was kept low. CONCLUSIONS AND RELEVANCE: Testosterone treatment appears to be effective and efficacious in reducing depressive symptoms in men, particularly when higher-dosage regimens were applied in carefully selected samples. However, given the heterogeneity of the included RCTs, more preregistered trials are needed that explicitly examine depression as the primary end point and consider relevant moderators.

来源:JAMA Psychiatry,查看原文。版权归原作者所有。

引用

  1. Walther A, Breidenstein J, Miller R, et al. Association of Testosterone Treatment With Alleviation of Depressive Symptoms in Men: A Systematic Review and Meta-analysis. JAMA Psychiatry. 2019. PMID: 30427999. doi:10.1001/jamapsychiatry.2018.2734

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。